364 related articles for article (PubMed ID: 30557872)
1. Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing.
Hu S; Yuan Y; Song Z; Yan D; Kong X
Cell Physiol Biochem; 2018; 51(6):2509-2522. PubMed ID: 30557872
[TBL] [Abstract][Full Text] [Related]
2. Analysis of microRNA (miRNA) expression profiles reveals 11 key biomarkers associated with non-small cell lung cancer.
Wang K; Chen M; Wu W
World J Surg Oncol; 2017 Sep; 15(1):175. PubMed ID: 28927412
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14.
Yu F; Liu JB; Wu ZJ; Xie WT; Zhong XJ; Hou LK; Wu W; Lu HM; Jiang XH; Jiang JJ; Cao ZY; Cong GJ; Shi MX; Jia CY; Lu GX; Song YC; Chai L; Lv ZW; Wu CY; Ma YS; Fu D
Cancer Lett; 2018 Jul; 427():74-84. PubMed ID: 29702194
[TBL] [Abstract][Full Text] [Related]
4. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
[TBL] [Abstract][Full Text] [Related]
5. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J
Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
8. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
Gong J; He L; Ma J; Zhang J; Wang L; Wang J
J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
[TBL] [Abstract][Full Text] [Related]
9. miR-15a enhances the anticancer effects of cisplatin in the resistant non-small cell lung cancer cells.
Bozok Çetintaş V; Tetik Vardarlı A; Düzgün Z; Tezcanlı Kaymaz B; Açıkgöz E; Aktuğ H; Kosova Can B; Gündüz C; Eroğlu Z
Tumour Biol; 2016 Feb; 37(2):1739-51. PubMed ID: 26314859
[TBL] [Abstract][Full Text] [Related]
10. Microarray data analysis on gene and miRNA expression to identify biomarkers in non-small cell lung cancer.
Jin X; Guan Y; Zhang Z; Wang H
BMC Cancer; 2020 Apr; 20(1):329. PubMed ID: 32299382
[TBL] [Abstract][Full Text] [Related]
11. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
12. Integrated microRNA and gene expression profiling reveals the crucial miRNAs in curcumin anti-lung cancer cell invasion.
Zhan JW; Jiao DM; Wang Y; Song J; Wu JH; Wu LJ; Chen QY; Ma SL
Thorac Cancer; 2017 Sep; 8(5):461-470. PubMed ID: 28660665
[TBL] [Abstract][Full Text] [Related]
13. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
[TBL] [Abstract][Full Text] [Related]
14. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
15. [Differential expression of serum miRNAs in patients with advanced non-small cell lung cancer treated by gifitinib before and after acquiring drug resistance].
Huang Q; Li D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 43(12):1288-1293. PubMed ID: 30643043
[TBL] [Abstract][Full Text] [Related]
16. Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib.
Wang C; Ding S; Sun B; Shen L; Xiao L; Han Z; Huang H
Pharmacol Res; 2020 Nov; 161():105110. PubMed ID: 32755614
[TBL] [Abstract][Full Text] [Related]
17. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
[TBL] [Abstract][Full Text] [Related]
19. SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p.
Cui F; Hao ZX; Li J; Zhang YL; Li XK; He JX
Mol Genet Genomic Med; 2020 May; 8(5):e1195. PubMed ID: 32130794
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.
Ge X; Zheng L; Huang M; Wang Y; Bi F
Mol Med Rep; 2015 Jan; 11(1):333-40. PubMed ID: 25339453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
